GlassScriptPhysician profile
Emily C Essert
NPI 1003129859
$3,860.75
in general payments reported to CMS, 2019-2025
31 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.89 · 2022: $18.07 · 2023: $538 · 2024: $1,586 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,828.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $759.74 | 2023-2025 | |
| Novo Nordisk INC | $463.96 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $358.26 | 2022-2025 | |
| Amgen INC. | $344.64 | 2020-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $198.96 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $189.52 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $174.00 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Eisai INC. | $153.54 | 2024-2025 | |
| Lundbeck LLC | $140.78 | 2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $117.69 | 2024-2025 | Austedo Xr, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.75 | 2024-2025 | Xifaxan |
| Boston Scientific Corporation | $106.82 | 2023-2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $103.76 | 2023-2024 | Xarelto |
| Abbott Laboratories | $86.00 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $66.75 | 2023-2025 | Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $55.31 | 2023-2025 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $47.67 | 2024-2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $46.32 | 2024 | Keveyis |
| Phathom Pharmaceuticals, INC. | $44.77 | 2024 | Voquezna |
| Dexcom, INC. | $42.76 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $33.83 | 2024-2025 | Capvaxive, Gardasil 9, Vaqta |
| Kowa Pharmaceuticals America, INC. | $27.48 | 2024-2025 | Zoryve |
| Axsome Therapeutics, INC. | $25.47 | 2025 | Auvelity |
| Corcept Therapeutics | $25.24 | 2024 | Korlym |
| Pulmonx Corporation | $24.78 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Axonics, INC. | $24.16 | 2023 | Axonics |
| Alnylam Pharmaceuticals INC. | $21.67 | 2024 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.42 | 2024 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $17.13 | 2025 | Trintellix |
| Philips North America LLC | $16.17 | 2025 | Extended Holter |
| Acella Pharmaceuticals, LLC | $15.40 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Essert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.